Liquid biopsies (LBs), particularly using circulating tumor DNA (ctDNA), are expected to
revolutionize precision oncology and blood-based cancer screening. Recent technological …

Cancer cells accumulate many genetic alterations throughout their lifetime, but only a few of
them drive cancer progression, termed driver mutations. Driver mutations may vary between …

In the current era of precision medicine, the identification of genomic alterations has
revolutionised the management of patients with solid tumours. Recent advances in the …

Background Liquid biopsy (LB) is a rapidly evolving diagnostic tool for precision oncology
that has recently found its way into routine practice as an adjunct to tissue biopsy (TB). The …

Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden
and provide unique insights into the evolving molecular landscape of cancers under the …

Cell-free DNA molecules are released into the plasma via apoptotic or necrotic events and
active release mechanisms, which carry the genetic and epigenetic information of its origin …

In the era of precision oncology, use of circulating tumor DNA (ctDNA) is emerging as a
minimally invasive approach for the diagnosis and management of patients with cancer and …

PURPOSE Immune checkpoint inhibitors (ICIs) are increasingly being used in non–small-
cell lung cancer (NSCLC), yet biomarkers predicting their benefit are lacking. We evaluated …

Over the last decade, great advancements have been made in the field of liquid biopsy
through extensive research and the development of new technologies that facilitate the use …

Background Analysis of circulating free DNA (cfDNA) is a promising tool for personalized
management of colorectal cancer (CRC) patients. Untargeted cfDNA analysis using whole …